Predictors of Poor Outcomes after Transcatheter Aortic Valve Replacement: Results from the PARTNER Trial Suzanne V. Arnold, Matthew R. Reynolds, Yang Lei, Elizabeth A. Magnuson, Ajay J. Kirtane, Susheel K. Kodali, Alan Zajarias, Vinod H. Thourani, Philip Green, Josep Rodés-Cabau, Nirat Beohar, Michael J. Mack, Martin B. Leon and David J. Cohen on behalf of the PARTNER Investigators Circulation. published online May 23, 2014; Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2014 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at: http://circ.ahajournals.org/content/early/2014/05/23/CIRCULATIONAHA.113.007477

Data Supplement (unedited) at: http://circ.ahajournals.org/content/suppl/2014/05/23/CIRCULATIONAHA.113.007477.DC1.html

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: http://www.lww.com/reprints Subscriptions: Information about subscribing to Circulation is online at: http://circ.ahajournals.org//subscriptions/

Downloaded from http://circ.ahajournals.org/ at Marquette University on August 21, 2014

DOI: 10.1161/CIRCULATIONAHA.113.007477

Predictors of Poor Outcomes after Transcatheter Aortic Valve Replacement: Results from the PARTNER Trial Running title: Arnold et al.; Predictors of poor outcome after TAVR Suzanne V. Arnold, MD, MHA1,2; Matthew R. Reynolds, MD, MSc3; Yang Lei, MS1; Elizabeth A. Magnuson, ScD1,2; Ajay J. Kirtane, MD, SM4; Susheel K. Kodali, MD4; Alan Zajarias, MD5; Vinod H. Thourani, MD6; Philip Green, MD4; Josep Rodés-Cabau, MD7; Nirat Beohar, MD8; Michael J. Mack, MD9; Martin B. Leon, MD4; David J. Cohen, MD, MSc1,2 on behalf of the PARTNER Investigators 1

Saint Luke’s Mid America Heart Institute, Kansas City, MO; 2University of Missouri-Kansas City Ci City, ty, Ka ty Kansas Kans sas City, City, MO; 3Harvard Clinical Research Res esearch Institute, Boston, Boost ston o , MA; 4ColumbiaP Presbyterian resbyyteerian nH Hospital, ospi os pita pi taal, l, N New ew wY York, ork, or k,, N NY; Y;; 5Wa Washington Was shingttonn U University, n veersiity, ni ity, y S St. t. Lou Louis, ouis iss, MO M MO;; 6Em Emory Emor oryy or

Un University School Sch ch hool ooff M Medicine, ed diccin ine, A Atlanta, t ant tl anta, GA GA; 7La Lavall Un Uni University, iversitty, ive ty Que Quebec, ebec,, Canad ebe C Canada; a da;; 8Col Columbia C olum mbiia ia University Division Cardiology Mount Sinai Medical Center, Miami Beach, FL; Univ Un iver iv ersi sity ty D iv vis isio ionn off C arrdi d ol olog ogyy att M og ountt S ou in naii M ed dic icaal C en nteer, M iaamii B e ch ea ch,, FL L; 9Ba Baylor Bay ylor ylo or Heal He Healthcare alth al thca th care ca re S System, yste ys tem te m, P Plano, lano la no, TX no Address for Correspondence: Suzanne V. Arnold MD MHA Saint Luke’s Mid America Heart Institute University of Missouri-Kansas City School of Medicine 4401 Wornall Rd Kansas City, MO 64111 Tel: 816-932-8606 Fax: 816-932-5613 E-mail: [email protected] Journal Subject Codes: Treatment:[23] Catheter-based coronary and valvular interventions:other, Ethics and policy:[100] Health policy and outcome research

1 Downloaded from http://circ.ahajournals.org/ at Marquette University on August 21, 2014

DOI: 10.1161/CIRCULATIONAHA.113.007477

Abstract Background—Transcatheter Aortic Valve Replacement (TAVR) is a less invasive option for treatment of high-risk patients with severe aortic stenosis. We sought to identify patients at highrisk for poor outcome after TAVR, using a novel definition of outcome that integrates quality of life (QoL) with mortality. Methods and Results—Among 2137 patients who underwent TAVR in the PARTNER trial or associated continued access registry, QoL was assessed using the Kansas City Cardiomyopathy Questionnaire-Overall Summary Scale (KCCQ-OS, range 0-100; higher=better) at baseline, 1, 6, and 12 months. A poor 6-month outcome—defined as death, KCCQ-OS

Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial.

Transcatheter aortic valve replacement (TAVR) is a less invasive option for treatment of high-risk patients with severe aortic stenosis. We sought to ...
2MB Sizes 0 Downloads 6 Views